TrialMultiple sclerosis (Houndmills, Basingstoke, England)2022

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.

Stephen L Hauser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.